The use of genome-scale sequencing allows for identification of genetic findings beyond the origi-
findings will expand beyond those currently recommended by the ACMG. The ClinGen AWG evidence reports and summary scores are not intended as classifications of actionability, rather they provide a resource to aid decision makers as they determine best practices regarding secondary findings. The ClinGen AWG is working with the ACMG Secondary Findings Committee to update future iterations of their secondary findings list.
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INTRODUCTION
The use of genome-scale sequencing (i.e., exome and genome sequencing) in clinical practice and research settings is increasing due to diagnostic utility, decreasing costs, and improved access to testing.
As this use increases, providers, patients, and policy-makers must decide how to act upon results beyond the original indication for testing (secondary findings). The return of relevant secondary findings allows patients and providers the opportunity to implement medical interventions that could improve future health outcomes. This concept is referred to as "clinical actionability" (Hunter et al., 2016) .
While most stakeholders, including patients and clinicians, endorse that secondary findings should be offered to patients undergoing clinical sequencing, the criteria for determining which results to return remains largely unclear (Mackley, Fletcher, Parker, Watkins, & Ormondroyd, 2017) . To address this issue, the American College of Medical Genetics and Genomics (ACMG) developed a list of secondary findings recommended to be offered for return to patients, with plans
for updating and refinement of this list over time (Green et al., 2013) .
This list was most recently updated in 2017, and is referred to as the ACMG SF v2.0 (Kalia et al., 2017) .
To create a centralized resource for summarizing and assessing evidence related to clinical actionability, the Clinical Genome Resource (ClinGen) created the Actionability Working Group (AWG).
The ClinGen AWG defines clinical actionability of secondary findings as the implementation of an available clinical intervention in asymptomatic or previously undiagnosed adults with the goal of ameliorating or preventing a future negative health outcome.
The ClinGen AWG previously published its methods development and actionability scores for the genes/disorders originally recommended for return by the ACMG (Green et al., 2013; Hunter et al., 2016) . Since this time, scoring by the ClinGen AWG has continued and expanded beyond those genes and conditions included in the ACMG SF v2.0 list. The findings of the AWG are a publicly-available resource that can be accessed and used by a variety of stakeholders to guide the implementation and evaluation of policy-making and recommendations surrounding the return of secondary findings to patients.
In this paper we present updated findings of the ClinGen AWG and compare the scoring metric results for genetic disorders on the ACMG SF v2.0 list versus those not on the list (either because they have not yet been evaluated by the ACMG or because they were excluded from the list).
MATERIALS AND METHODS
The ClinGen AWG's protocol for standardized evidence synthesis and generation of consensus scores has been published elsewhere (Hunter et al., 2016) . Briefly, the AWG uses a standardized protocol to generate a synthesis of available evidence regarding clinical actionability for each topic (i.e., the genetic disorder and associated gene(s)).
Nominations for topics considered by the AWG come from a variety of sources (e.g., AWG members, other ClinGen collaborators, and external groups, including other National Institutes of Health-funded projects). The AWG then applies a scoring metric to generate actionability scores based on the information in these reports. For each topic, the AWG may score multiple outcome-intervention pairs. For example, hereditary breast and ovarian cancer was scored using three outcome and intervention pairs: (1) breast cancer and surveillance, (2) breast cancer and risk-reducing surgery, and (3) ovarian cancer and risk-reducing surgery. For each outcome-intervention pair, AWG consensus scores are generated for four domains related to clinical actionability on a scale of 0 to 3: (1) severity of the outcome; (2) likelihood that the outcome will occur (penetrance); (3) effectiveness of the intervention to modify the outcome; and (4) nature of the intervention (a measure of the burden and risk to the patient) (Table 1 ). In addition, the domains of likelihood and effectiveness are assigned a letter score to represent the evidence base. Initial scoring is performed by multiple members of the AWG independently. These scorers include a core team of clinical geneticists and genetic counselors, as well as invited clinicians with topic-specific expertise, such as cardiology. Following group discussion, AWG members then provide a final score with the consensus scores representing the most frequent final score (i.e., mode of the score distribution). Final evidence reports and consensus scores for topics assessed to date are available on the ClinGen website (www.clinicalgenome.org).
Selection of outcome: Intervention pairs for analysis
For the present study, we compiled all the AWG outcome-intervention consensus scores generated through February 2018. For the purposes of this analysis, we selected only a single outcome-intervention pair for each topic to give each topic equal weight in the analysis.
To prioritize pairs for the analysis, we computed a summary score for each outcome and intervention by adding scores across the four domains of actionability. For each topic, we used the outcomeintervention pair with the highest summary score. When multiple TA B L E 1 ClinGen Actionability Working Group semi-quantitative score metric (Originally published in Hunter et al., 2016, outcome-intervention pairs tied for the highest summary score, we considered the individual domains to determine which pair to use in our analysis, as follows. If scoring for the four domains was consistent across outcome-intervention pairs, we included that scoring pattern in the analyses once, though it could be attributed to more than one outcome-intervention pair. For example, while two outcome-intervention pairs (recurrent serositis-colchicine and joint problems-colchicine) tied for the highest summary score in Familial Mediterranean Fever (autosomal dominant), both pairs had the same scoring pattern (severity = 2, likelihood = 3, effectiveness = 3, and nature of the intervention = 2). Thus, we only included these scores once in the analysis. If the individual domains of the outcomeintervention pairs differed, we prioritized the pair with the highest score in the following domains as tiebreakers: effectiveness, followed by severity, followed by likelihood.
For situations where the AWG scored topics separately by categories defined by gene (e.g., BRCA1 and BRCA2 were scored separately for hereditary breast and ovarian cancer) or zygosity (e.g., familial hypercholesterolemia), we used one pair for each category.
Analysis approach
Each topic may include more than one gene and/or more than one condition. Thus, for the purposes of this analysis, it was necessary for us to decide how to classify each topic in terms of its inclusion on the ACMG SF v2.0 list (Kalia et al., 2017) . There were some topics assessed by the AWG where only a subset of the genes was included by the ACMG (e.g., the AWG assessed MLH1, MSH2, MSH6, PMS2, and EPCAM for Lynch syndrome while EPCAM was not included on the ACMG SF v2.0 list).
For this analysis, these topics were still considered to be listed on the 
RESULTS
The AWG has scored a total of 78 topics associated with 127 genes, where 14 of these topics have been updated since the original publication of the actionability scores (Supporting Information Table S1 ) (Hunter et al., 2016) . Across these topics, the AWG has scored a total of 213 outcome-intervention pairs. Applying the selection criteria outlined above, we determined 88 outcome-intervention pairs were eligible for analysis, which accounts for the 78 topics, four of which had gene-specific scoring (Table 2 , Supporting Information Table S1 ).
Thirty-six of these pairs represent genes/disorders currently included on the ACMG SF v2.0 list.
Comparison of summary scores
The mean summary score (added across the four domains) of the pairs included on the ACMG SF v2.0 list was significantly higher than those not currently included on the list (10.0 vs. 9.2, P < 0.01; Table 2 ). In addition, the distribution of the summary scores is skewed higher for topics on the ACMG SF v2.0 list (P < 0.05; Table 2 , Figure 1 ) than for topics not on the list.
TA B L E 2 Summary of 88 outcome-intervention pairs
All (n = 88) ACMG (n = 36) Non-ACMG (n = 52) 
Scores related to the outcome
The outcomes related to topics on the ACMG SF v2.0 list had significantly higher mean domain scores for severity and likelihood of the outcome, compared to those not on the ACMG SF v2.0 list (P < 0.05; Table 2 ). To account for a non-normal distribution of these scores, a nonparametric test was performed, which did not alter conclusions 
Scores related to the intervention
We found no difference in the mean domain scores for either the effectiveness or nature of the intervention ( Table 2 ). The range of scores for effectiveness was the same across both groups (1-3) (Figure 2c,d ).
Only one topic included in the analysis received a "0" score for nature of the intervention indicating a "high risk, poorly acceptable or intensive intervention," which was for liver transplantation to prevent morbidity associated with hereditary transthyretin-related amyloidosis, a topic not on the ACMG SF v2.0 list. 
Examination of highest scoring outcome-intervention pairs
Two topics scored a "3" across all four domains of actionability (summary score = 12), both of which are on the ACMG SF v2.0 list: LoeysDietz syndrome and Marfan syndrome. Nearly half (46%) of the 13 topics with a summary score of 11, however, represent genes/disorders that are not currently included on the ACMG SF v2.0 list (Table 3) .
Comparing all topics with a summary score of 11 across domains reveals that all but one (familial thoracic aortic aneurysm and dissection) have the same scoring pattern across the four domains (severity = 2, likelihood = 3, effectiveness = 3, nature of the intervention = 3).
This indicates that each of these topics represents gene disorders with a moderately severe outcome of at least 40% penetrance that could be altered by a highly effective and a lower risk/more medically acceptable intervention.
DISCUSSION
The use of genomic sequencing is increasing, with stakeholders faced with the challenge of deciding whether to report and how to prioritize the return of secondary findings. Secondary findings offer the opportunity to provide valuable clinical information to implement interventions and minimize or prevent future negative clinical outcomes. However, a centralized resource of available evidence on clinical actionability to guide decision-making by stakeholders has been lacking. The ClinGen AWG was established to address this need.
Among the 78 topics (127 genes) that have been scored by the ClinGen AWG, we found that the topics already on the ACMG SF v2.0 list had higher overall summary scores than the topics not on the list.
These differences in scoring tended to be due to aspects of the outcome (higher level of severity and likelihood). These results could indicate prioritization of topics by the ACMG based on the severity and likelihood of outcomes. As part of our analyses, we found several topics that do not appear on the ACMG SF v2.0 list but do appear to fit the pattern of conditions already recommended for return by the ACMG (Table 3) only four laboratories actively searched for secondary findings and multiple laboratories actively took efforts to reduce the identification of these findings though bioinformatic filters and limited analyses (Vears, Senecal, & Borry, 2017) . These differences between United
States and international practice may be influenced by the fact that international guidelines do not endorse actively seeking and reporting these findings as routine practice (Boycott et al., 2015; van El et al., 2013) . Standardized assessments, like those produced by the ClinGen AWG, offer a resource for laboratory directors and other stakeholders during future decision-making regarding the return of secondary findings to patients.
Importantly, perspectives on what results may be considered actionable may differ between patients, providers, and other decision makers (e.g., laboratory directors, payers). Currently, the ClinGen AWG only considers interventions that can confer medical actionability (i.e., the availability of a clinical intervention) and does not consider personal utility (i.e., nonclinical interventions or benefits beyond clinical utility) when making its recommendations (Kohler et al., 2017) . When viewed as a whole, studies of a variety of stakeholders (i.e., patients, members of the public, health care professionals, researchers) report that over half of those surveyed endorsed the return of all secondary findings, regardless of actionability or clinical relevance; however, in some studies participants acknowledged becoming less inclined to receive all findings following further discussion (Mackley et al., 2017) .
When examined by group, the desire to receive all findings, regardless of medical actionability, was more frequently expressed by patients and based on reasons related to patient empowerment. Providers, on the other hand, were more likely than patients to favor a more conservative approach due to concerns regarding the potential distress and the resources required to follow up secondary findings (Mackley et al., 2017) . Given these differences in perspectives from patients and providers or other decision makers, the work of the ClinGen AWG may serve as an important resource for clinical decision-making.
While using the summary score across the four domains may help identify the "most actionable" topics for most users, specific domains (such as severity or effectiveness) may take precedence for some decision makers. For example, a case study reporting the selection of which secondary findings to return to research study participants found that, in addition to information scored from a related semi-quantitative metric, decision makers utilized additional subjective factors (e.g., cost
and likelihood of identifying a finding with a low population prevalence) to determine the final list. The conclusion was that the actionability criteria considered in the metric could not be used to "just blindly turn the crank" to determine which findings to return; rather they should be considered a starting point for more nuanced decisionmaking (Lazaro-Munoz, Conley, Davis, Prince, & Cadigan, 2017) . In addition, the relative value of domains may differ between decision makers and patients. Within a Danish population-based discrete choice experiment, the population preference for reporting favored the severity and likelihood of the result and gave less weight to the existence of preventive measures and treatment. Therefore, individuals may value more than just findings that could inform clinical decisionmaking and may also focus more on those findings that are most likely to have a negative impact on their future health (Ploug & Holm, 2017 ). 
Limitations
There is no true gold standard to evaluate which secondary findings are truly "actionable" at an individual or population level. Therefore, this analysis primarily focuses on a comparison of the currently available information from the ClinGen AWG and the ACMG to guide decision makers. In addition, the use of the summary score for selection of outcome-intervention pairs for the analysis may not represent what some groups would consider the most actionable pair (e.g., selecting the pair based on the highest severity or likelihood). Additionally, the scores that were used for the ClinGen AWG are the final group consensus scores, and do not account for the variation in scores from individual members of the group.
Some components of the semi-quantitative metric require subjective judgment by individual scorers, in particular the severity of the outcome and the nature of the intervention. It is acknowledged by the AWG that individual perspectives, including perspectives among clinicians and patients, may vary regarding these domains. Future work of the AWG will examine how well the consensus scores reflect the views of the general patient population. In addition, while the use of objective criteria to determine the effectiveness of the intervention is desirable, the variability in how these measures may be reported and the heterogeneity of clinical outcomes considered (e.g., mortality, quality of life, severity of symptoms) necessitates the use of relatively subjective criteria (e.g., "moderately effective").
Lastly, based on the AWG protocol reliance on synthesized evidence, it is difficult for the level of evidence related to likelihood to rise above a level C (or Tier 3 evidence), given that systematic reviews and meta-analyses of penetrance data are rare. This points toward the need for methods development to be able to identify additional sources of data (including unpublished data) to inform the evidence on likelihood, particularly in an unselected population.
Despite these limitations, these findings provide valuable information to illuminate a standardized process for evaluating the complicated issues surrounding secondary findings.
Conclusions
The ongoing ClinGen AWG process has thus far created summary reports and scores for a total of 78 topics (including 127 genes). The
ClinGen AWG evidence reports and summary scores are intended to aid decision makers as they determine best practices for returning secondary genomic findings to individuals. As a part of this effort, the ClinGen AWG is working closely with the ACMG Secondary Findings Committee to update future iterations of their recommended secondary findings list.
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